JP2024040951A - アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物 - Google Patents

アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物 Download PDF

Info

Publication number
JP2024040951A
JP2024040951A JP2022145626A JP2022145626A JP2024040951A JP 2024040951 A JP2024040951 A JP 2024040951A JP 2022145626 A JP2022145626 A JP 2022145626A JP 2022145626 A JP2022145626 A JP 2022145626A JP 2024040951 A JP2024040951 A JP 2024040951A
Authority
JP
Japan
Prior art keywords
solid dispersion
enzalutamide
apalutamide
pharmaceutical composition
methylhesperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022145626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024040951A5 (enExample
Inventor
正哉 中西
Masaya Nakanishi
雅志 千々石
Masashi Chichiishi
恭佑 柴谷
Kyosuke Shibatani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Towa Pharmaceutical Co Ltd
Original Assignee
Towa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Towa Pharmaceutical Co Ltd filed Critical Towa Pharmaceutical Co Ltd
Priority to JP2022145626A priority Critical patent/JP2024040951A/ja
Publication of JP2024040951A publication Critical patent/JP2024040951A/ja
Publication of JP2024040951A5 publication Critical patent/JP2024040951A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022145626A 2022-09-13 2022-09-13 アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物 Pending JP2024040951A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022145626A JP2024040951A (ja) 2022-09-13 2022-09-13 アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022145626A JP2024040951A (ja) 2022-09-13 2022-09-13 アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物

Publications (2)

Publication Number Publication Date
JP2024040951A true JP2024040951A (ja) 2024-03-26
JP2024040951A5 JP2024040951A5 (enExample) 2025-09-22

Family

ID=90369106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022145626A Pending JP2024040951A (ja) 2022-09-13 2022-09-13 アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物

Country Status (1)

Country Link
JP (1) JP2024040951A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
WO2025212071A1 (en) * 2024-04-05 2025-10-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A solid dispersion of enzalutamide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527411A (ja) * 2012-09-11 2015-09-17 メディベイション プロステイト セラピューティクス， インコーポレイテッド エンザルタミドの製剤
JP2017507928A (ja) * 2014-02-05 2017-03-23 レツク・フアーマシユーテイカルズ・デー・デー アンドロゲン受容体アンタゴニストの固体医薬組成物
WO2018199282A1 (ja) * 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
WO2022165423A1 (en) * 2021-02-01 2022-08-04 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527411A (ja) * 2012-09-11 2015-09-17 メディベイション プロステイト セラピューティクス， インコーポレイテッド エンザルタミドの製剤
JP2017507928A (ja) * 2014-02-05 2017-03-23 レツク・フアーマシユーテイカルズ・デー・デー アンドロゲン受容体アンタゴニストの固体医薬組成物
WO2018199282A1 (ja) * 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
WO2022165423A1 (en) * 2021-02-01 2022-08-04 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF HEALTH SCIENCES, vol. 6, no. 4, JPN6026027158, 2022, pages 12074 - 12087, ISSN: 0005895644 *
医薬品添加物辞典２００７, vol. ２００７年７月２５日, 第１刷, JPN6026027157, pages 268, ISSN: 0005895645 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
WO2025212071A1 (en) * 2024-04-05 2025-10-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A solid dispersion of enzalutamide

Similar Documents

Publication Publication Date Title
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
Shah et al. Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
JP6192244B2 (ja) 改良されたバイオアベイラビリティを有する薬学的組成物
JP5484910B2 (ja) レバプラザン含有の固体分散体及びその製造方法
JP7172997B2 (ja) エンザルタミドを含有する経口投与用医薬組成物
JP2018184410A (ja) 非晶質ダパグリフロジンを含有する製剤
KR101723266B1 (ko) 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법
WO2012013088A1 (zh) 决奈达隆固体分散体及其制备方法
TW201919621A (zh) 醫藥製劑
CN103260605B (zh) 阿齐沙坦固体分散体及其制备方法和药物组合物
Xue et al. A combined utilization of Plasdone-S630 and HPMCAS-HF in ziprasidone hydrochloride solid dispersion by hot-melt extrusion to enhance the oral bioavailability and no food effect
AU2017256184A1 (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
Varshosaz et al. Enhancement of dissolution rate of fenofibrate by spray drying technique: Comparison of eudragit E-100, solutol® HS15 and hydroxypropyl cellulose as carriers
JP2024094310A (ja) アパルタミドの固体分散体を含む薬学的組成物
JP7752487B2 (ja) アピキサバン含有固体分散体
KR101617119B1 (ko) 셀레콕시브를 포함하는 경구용 정제의 제조방법
JP2024064876A (ja) 医薬組成物
WO2015199115A1 (ja) 経口投与用医薬組成物
CN112294765A (zh) 一种阿可拉定的无定型及其制备方法和用途
KR101956586B1 (ko) 약제학적 조성물 및 이의 제조방법
TWI520752B (zh) 決奈達隆固體分散體及其製備方法
CN121489880A (zh) 一种新的厄贝沙坦组合物的制备方法
KR20160082170A (ko) 리바록사반 함유 경구용 고형제제
CN121265811A (zh) 一种缬沙坦的口服固体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260630